rewirebio.iobenchmarks
Protocol

Held-out trials, immunotherapy response AUROC, equal mean over six trials

Classify RECIST complete or partial responders in the immunotherapy arms of six held-out trials from pretreatment RNA-seq, scoring AUROC within each trial and averaging the six trials equally.

10 evaluations · 10 results

Overview

An explanatory profile has not yet been reviewed for this record.

Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.

10 recorded evaluations, 10 metric rows. A comparison chart has not yet been validated for these results. The table retains the individual findings and their sources.

View coverage and remaining gaps across all benchmarks

Results

Results are available, but no reviewed comparison panel is linked in this release.

All evaluations

10 evaluations · 10 results. Different protocols are not a single leaderboard.

Protocol: Held-out trials, immunotherapy response AUROC, equal mean over six trials · Dataset subset: Immunotherapy arms of six held-out trials with evaluable response

Sorted by AUROC (AUROC for RECIST complete or partial response against other evaluable responses, immunotherapy arms, equal mean over six held-out trials) (higher is better). The best value in each column is highlighted. Decimals are rounded for display; each value links to the printed value and its source.

All 10 result rows with coverage, uncertainty and sources
Filter evaluations

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configurationProtocol and datasetFindingEvidence and details
Configuration: BulkFormer 147M (Ladon report comparator)Protocol: Held-out trials, immunotherapy response AUROC, equal mean over six trials
Dataset subset: Immunotherapy arms of six held-out trials with evaluable response
0.629 AUROC (AUROC for RECIST complete or partial response against other evaluable responses, immunotherapy arms, equal mean over six held-out trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

BulkFormer, held-out trials immunotherapy response AUROC

ladon-20261115-protocol-trials-response-auroc

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 6 (page 10), row 'BulkFormer', bar label
Configuration: BulkRNABert, published Hugging Face checkpoint (Ladon report comparator)Protocol: Held-out trials, immunotherapy response AUROC, equal mean over six trials
Dataset subset: Immunotherapy arms of six held-out trials with evaluable response
0.612 AUROC (AUROC for RECIST complete or partial response against other evaluable responses, immunotherapy arms, equal mean over six held-out trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

BulkRNABert, held-out trials immunotherapy response AUROC

ladon-20261115-protocol-trials-response-auroc

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 6 (page 10), row 'BulkRNABert', bar label
Configuration: Clinical covariates encoded by BMRetriever-7B (Ladon report baseline)Protocol: Held-out trials, immunotherapy response AUROC, equal mean over six trials
Dataset subset: Immunotherapy arms of six held-out trials with evaluable response
0.515 AUROC (AUROC for RECIST complete or partial response against other evaluable responses, immunotherapy arms, equal mean over six held-out trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Clinical covariates (BMRetriever), held-out trials immunotherapy response AUROC

ladon-20261115-protocol-trials-response-auroc

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 6 (page 10), row 'Clinical covariates (BMRetriever)', bar label
Method: Differential gene expression signature (Ladon report)Protocol: Held-out trials, immunotherapy response AUROC, equal mean over six trials
Dataset subset: Immunotherapy arms of six held-out trials with evaluable response
0.633 AUROC (AUROC for RECIST complete or partial response against other evaluable responses, immunotherapy arms, equal mean over six held-out trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Differential gene expression, held-out trials immunotherapy response AUROC

ladon-20261115-protocol-trials-response-auroc

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 6 (page 10), row 'Differential gene expression', bar label
Method: Gene TPM features with academic-only context (Ladon report)Protocol: Held-out trials, immunotherapy response AUROC, equal mean over six trials
Dataset subset: Immunotherapy arms of six held-out trials with evaluable response
0.613 AUROC (AUROC for RECIST complete or partial response against other evaluable responses, immunotherapy arms, equal mean over six held-out trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Gene TPM, held-out trials immunotherapy response AUROC

ladon-20261115-protocol-trials-response-auroc

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 6 (page 10), row 'Gene TPM', bar label
Method: IMPRESProtocol: Held-out trials, immunotherapy response AUROC, equal mean over six trials
Dataset subset: Immunotherapy arms of six held-out trials with evaluable response
0.505 AUROC (AUROC for RECIST complete or partial response against other evaluable responses, immunotherapy arms, equal mean over six held-out trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

IMPRES, held-out trials immunotherapy response AUROC

ladon-20261115-protocol-trials-response-auroc

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 6 (page 10), row 'IMPRES', bar label
Configuration: Ladon, response mid-trained, PCA 128 + TabICL v2 (held-out trial response)Protocol: Held-out trials, immunotherapy response AUROC, equal mean over six trials
Dataset subset: Immunotherapy arms of six held-out trials with evaluable response
0.673 AUROC (AUROC for RECIST complete or partial response against other evaluable responses, immunotherapy arms, equal mean over six held-out trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Ladon, held-out trials immunotherapy response AUROC

ladon-20261115-protocol-trials-response-auroc

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 6 (page 10), row 'Ladon', bar label
Method: PD-L1 mRNA (CD274 expression)Protocol: Held-out trials, immunotherapy response AUROC, equal mean over six trials
Dataset subset: Immunotherapy arms of six held-out trials with evaluable response
0.597 AUROC (AUROC for RECIST complete or partial response against other evaluable responses, immunotherapy arms, equal mean over six held-out trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

PD-L1 mRNA, held-out trials immunotherapy response AUROC

ladon-20261115-protocol-trials-response-auroc

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 6 (page 10), row 'PD-L1 mRNA', bar label
Method: T-effector / IFN-gamma signatureProtocol: Held-out trials, immunotherapy response AUROC, equal mean over six trials
Dataset subset: Immunotherapy arms of six held-out trials with evaluable response
0.628 AUROC (AUROC for RECIST complete or partial response against other evaluable responses, immunotherapy arms, equal mean over six held-out trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

T-effector / IFN-γ, held-out trials immunotherapy response AUROC

ladon-20261115-protocol-trials-response-auroc

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 6 (page 10), row 'T-effector / IFN-γ', bar label
Method: TIDEProtocol: Held-out trials, immunotherapy response AUROC, equal mean over six trials
Dataset subset: Immunotherapy arms of six held-out trials with evaluable response
0.492 AUROC (AUROC for RECIST complete or partial response against other evaluable responses, immunotherapy arms, equal mean over six held-out trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

TIDE, held-out trials immunotherapy response AUROC

ladon-20261115-protocol-trials-response-auroc

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 6 (page 10), row 'TIDE', bar label

Source checking is not independent reproduction. Release 2026-11-21-adc15377fab2.

Methods and evaluation design

Procedure, tasks and evaluated configurations

Recorded evaluations

Each evaluation records what was tested and under which conditions.

Baseline coverage

Reference methods help show what a model adds beyond simple controls. We track a null control and a conventional method for each protocol.

0 of 2 active baseline roles have published Rewire measurements in this release. Measurements on a selected protocol do not establish coverage of an entire suite.

No execution recipe linked to this protocol. Recipe availability does not establish a completed evaluation.

Author-reported evaluations
10

Literature evidence is not a Rewire measurement. Executed but unpublished runs and private review status are not included.

Null control

Proposed control: requires review

Training-set class prior where supervised fitting is permitted

Protocol-specific applicability, permitted inputs, access, split, evaluator and execution requirements need review before implementation or execution.

This is a suggested selection rule, not a validated method or a measured score.

Conventional reference

Proposed control: requires review

Regularised classifier on simple permitted features, or protocol's conventional reference

Protocol-specific applicability, permitted inputs, access, split, evaluator and execution requirements need review before implementation or execution.

This is a suggested selection rule, not a validated method or a measured score.

Protocol coverage CSV (gzip) · Model evaluation matrix (gzip) · Source table (gzip) · Release and checksums (gzip)

Coverage is derived from release 2026-11-21-adc15377fab2. Source citations describe the original records; they do not validate an unreviewed baseline proposal. No results have been generated by this audit.

Run instructions

No runnable recipe has been reviewed for this protocol. Dataset access, model requirements, licences and compute requirements must be checked against its sources before execution.

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

0 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-adc15377fab2
Property and statementOriginal source and locationReview and provenance

No evidence rows match these filters. Choose another scope or clear the search.

Sources and history

Release 2026-11-21-adc15377fab2 · Record review: source checked

1 source record and release historyDownload this release (gzip)
Technical metadata and record identifiers

Technical metadata for this record is tracked under stable ID ladon-20261115-protocol-trials-response-auroc.

Source locator: Figure 6 (page 10) and caption; pages 15 and 16, Methods 'Immunotherapy response'

Related records

Suggest a correction